Next Article in Journal
Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma
Next Article in Special Issue
Uncovering Potential Therapeutic Targets in Colorectal Cancer by Deciphering Mutational Status and Expression of Druggable Oncogenes
Previous Article in Journal
Ovarian Cancer Stem Cells: Role in Metastasis and Opportunity for Therapeutic Targeting
Previous Article in Special Issue
Urinary Metabolic Signatures Detect Recurrences in Non-Muscle Invasive Bladder Cancer
Open AccessReview

Possible Biomarkers for Cancer Immunotherapy

Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan
Author to whom correspondence should be addressed.
Cancers 2019, 11(7), 935;
Received: 24 May 2019 / Revised: 18 June 2019 / Accepted: 30 June 2019 / Published: 3 July 2019
(This article belongs to the Special Issue New Biomarkers in Cancers)
PDF [385 KB, uploaded 3 July 2019]
  |     |  


Immune checkpoint inhibitors (ICIs) have drastically changed the clinical care of cancer. Although cancer immunotherapy has shown promise in various types of malignancies, thus far, the proportion of patients who can benefit from ICIs is relatively small. Immune-related adverse events and high cost are unavoidable problems. Therefore, biomarkers defining patients that are most likely to benefit from ICIs are urgently needed. The expression of programmed cell death-ligand 1 (PD-L1) is a logical biomarker for the prediction of response to anti-PD1/PD-L1 immunotherapies. However, its usefulness is currently debatable because of its varied definition, threshold, and spatial/temporal heterogeneity. Recently, it was reported that the tumor mutational burden, expression of neoantigens, mismatch repair status, and specific gene mutations may be markers for the success of treatment with ICIs. Moreover, it was suggested that the fecal microbiota prior to immunotherapy may play an important role in predicting the efficacy of ICIs. In this review, we focused on these potential biomarkers for cancer immunotherapy reported in recent clinical articles. Further studies are warranted to develop a predictive model using these biomarkers, with the aim of practicing precision medicine in cancer immunotherapy. View Full-Text
Keywords: cancer immunotherapy; programmed cell death-ligand 1 expression; tumor mutational burden; neoantigens; mismatch repair status; specific gene mutations; gut microbiome cancer immunotherapy; programmed cell death-ligand 1 expression; tumor mutational burden; neoantigens; mismatch repair status; specific gene mutations; gut microbiome

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Otoshi, T.; Nagano, T.; Tachihara, M.; Nishimura, Y. Possible Biomarkers for Cancer Immunotherapy. Cancers 2019, 11, 935.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top